President @ GPS Pharmacy | Co-Founder & Director of Missions @ XIT -Time to build something that changes everything🎗️ @officialsashf — Forever my why 🤍
It takes so little.
A simple text. A quick call. A “thinking of you.”
When someone has cancer, you don’t need the perfect words to brighten their day. You just need to remind them you’re still there for them.
#CancerSupport#ChildhoodCancer#CancerAwareness#KeepInTouch #BeTheFriend #NoOneFightsAlone
🧬 Very Exciting ALL News — ANNOUNCED TODAY
ONE IV DOSE → 3/3 MRD-NEGATIVE COMPLETE RESPONSES
September 21, 2026: New early human results were announced today from VNX-101, an investigational gene-delivered immunotherapy being studied in patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
The first ALL results are small — but noteworthy:
3 patients treated.
3 MRD-negative complete responses.
All 3 confirmed by clonoSEQ.
One patient with extensive disease outside the bone marrow also achieved a complete response at all disease sites on PET by Day 28.
The first treated patient remained MRD-negative through Day 260 and then proceeded to stem-cell transplant while still in complete remission.
🧬 WHAT MAKES THIS DIFFERENT?
VNX-101 isn’t traditional CAR-T.
It uses an AAV vector to deliver genetic instructions in vivo. After a single IV administration, the patient’s liver is designed to continuously produce a CD19×CD3 T-cell engager, which brings the patient’s own T cells into contact with CD19-positive cancer cells.
In simple terms:
Instead of manufacturing cancer-fighting cells outside the body, this approach gives the body genetic instructions to continuously make a cancer-targeting therapy itself.
The platform is designed to avoid leukapheresis, ex-vivo CAR-T manufacturing and repeat therapeutic infusions.
🎗️ WHAT ABOUT CHILDREN WITH ALL?
This is particularly interesting for pediatric cancer because VNX-101 has already received FDA Rare Pediatric Disease designation, as well as Fast Track and Orphan Drug designations.
However, there is an important distinction for families:
Vironexis currently describes the actively enrolling VNX-101 trial as enrolling adults.
So this is not currently a treatment that every child with ALL can sign up to receive.
For families with a child or adolescent with relapsed/refractory CD19-positive ALL, it may still be worthwhile to have the treating oncologist contact the study team to ask about future pediatric enrollment and upcoming cohorts.
🔎 HOW TO FIND THE TRIAL
https://t.co/eD9ILQUqpY
Families should contact the trial through the study contact information listed on https://t.co/lxwGJukMY4 or have their oncologist contact the nearest participating center. The study team performs the actual prescreening and determines eligibility.
⚠️ IMPORTANT CONTEXT
3/3 MRD-negative complete responses is an encouraging early human signal — but three patients is still only three patients.
This is an early Phase 1/2 study, not evidence of a 100% response rate in a larger population and not evidence of a cure rate.
One of the patients subsequently underwent stem-cell transplantation, which also means longer-term remission after transplant cannot be attributed to VNX-101 alone.
Why XIT is watching 🧬
The concept is what makes this particularly compelling:
One IV administration → genetic instructions delivered inside the body → the patient’s own cells continuously manufacture a cancer-targeting immunotherapy.
If these early responses prove reproducible and durable in larger studies, this could represent an important new way to deliver cancer immunotherapy.
XIT Research Review: For educational and informational purposes only. This is not medical advice. Clinical-trial eligibility and treatment decisions should be discussed with the treating oncology team and study investigators.
#ALL #ChildhoodLeukemia #ChildhoodCancer #GeneTherapy #GeneticMedicine #Leukemia #MRDNegative #PediatricCancer #CancerResearch #Immunotherapy #ClinicalTrials #PrecisionMedicine #XIT #LetsXIT
https://t.co/FLkEBAFLg2
This is my daughter, Sasha. 🎗️
She loved to sing. She loved life. And she deserved better therapies.
Our children deserve more than therapies developed decades ago. They deserve treatments designed around the biology of their cancer. They deserve access to the extraordinary advances happening in genetic medicine, gene editing, cellular therapy, and precision oncology.
Our children deserve better therapies.
They deserve cures. 🎗️
#ChildhoodCancer #PediatricCancer #EwingSarcoma #CancerResearch #GeneEditing #PrecisionMedicine #CellTherapy #XIT
Care enough that someday, somewhere, something is different because you were here.
We don’t get to choose how much time we’re given.
But we do get to choose what we do with it.
Sasha died from cancer,
But.
She is still changing rooms she never entered.
On walls. On signs.
In conversations about cures.
In rooms filled with people who refuse to accept that the next child has to share her fate.
Thank you, Beat Childhood Cancer Foundation & Sarah Detling Bartosz , for helping her remind people that this fight is far from over.
None of us gets to decide how long we are here.
But while we are here, we do get to decide what we move.
What we question.
What we build.
What we refuse to accept.
Who we fight for.
What becomes different because we existed.
Sasha was just a little girl.
She didn’t have decades to build a legacy.
And yet her name is now woven into a movement fighting for a future she never got to have.
So maybe a meaningful life isn’t measured in years.
Maybe it’s measured in what keeps moving after we are gone.
There are diseases waiting for cures.
People waiting for someone to care.
Problems everyone has learned to live with.
Things in this world that are still broken because too many of us assume someone else will fix them.
Pick something.
We all leave eventually.
The question is what refuses to leave with us.
Sasha picked to fight for a cure.
And we are just getting started. 🎗️
https://t.co/D97mJ9AeRc
“Mom, how can I help patients too?”
The next patient who needs their emergency kit will never know your little hands helped.
But you’ll know. And that’s the best feeling of all.
A surprise visit to GPS Pharmacy today! 🤍💊
I couldn’t be more proud of our incredible team and the dedication, care, and hard work they bring to our patients and providers every single day.
It’s pretty special to look around and see how far GPS Pharmacy has come — but what makes me proudest is the team behind it all.
Proud of what we’ve built. Grateful for the people who make it possible. And excited for what’s ahead for GPS Pharmacy.
#TheFutureOfCompounding #GPS
🤩🎙️✨ WE’RE OFFICIALLY ON SPOTIFY! ✨🎙️🤩
Please follow and share & bring AM Lumina along on your commute! 🚗☕️💛
Having you follow our podcast would mean a great deal to us. 🪽 Take us with you — wherever your day takes you. 🎧✨
And we cannot wait for you to hear Episode 2. It’s going to be a BIG one. 🎗️
DIAGNOSIS DAY:
If frontline treatment is the same, does the hospital you choose really matter? 🏥
We’re talking about the questions, decisions, and everything we wish we had known on Day One.
🎙️💛 Follow Angel Moms Lumina on Spotify and come along for the ride. 🤩🪽✨
Spotify Link:
https://t.co/FTbVunha88
So incredibly proud of him. Can’t wait for you to see it. 🩵🎗️
A huge thank you to :
Annie Bartosz
@beatccorg
Sarah Detling Bartosz
for choosing Sebastian to be a part of something so meaningful. 🎗️🩵
@elonmusk I tell my Beast “thank you for driving me” all the time—just to make sure I’m on his good side before he becomes fully self-aware and decides to take me for a spin. 🤣🤖🖤
This is how you negotiate your pay.👏👏
And for the record… the best marketer our pharmacy has ever had.
Of course, fresh breath and the cutie-patootie tax was absolutely non-negotiable.
We miss you so much, Sasha.
Your personality. Your confidence. Your love for people, animals, and your love for life. 🎗️
Sasha loved coming to work with me. She especially loved when I brought her along to the vet visits — because she somehow always ended up getting special access to meet and love on all the animals there 🐶🐱🐰🦜🦎🐢🐍🦔🦦🐾🩷
#Entrepreneurship #PediatricCancerAwareness #ChildhoodCancerAwareness
“If MIT is your dream, make MIT your life. Learn for it. Dream about it. And never stop believing you belong there.”
And always remember—behind every success story is a whole lot of work that no one ever sees.
Dream big and Earn it ♥️
@MIT
We will miss you, @DollyParton . 🤍
Thank you for the music, the joy, and for inspiring our children.
I hope all of our angels get a front-row seat to your concert in Heaven. 🤍🕊️
A child should never survive one cancer only to face another caused by the treatment meant to save them.
We have to do better. 🎗️
Link :
https://t.co/wN0dqdt8W2
WE ARE SO EXCITED! 🧬🎗️
We were told this approval would take months, yet XIT Foundation’s application was approved in just weeks. We are incredibly grateful.
I can’t help but feel that our angel Sasha—and all her friends—had something to do with this. 🎗️
Now, the work begins.
We cannot wait for XIT to bridge the gap between groundbreaking therapies already producing extraordinary outcomes—and the precious children who deserve the chance to receive them.
https://t.co/D97mJ9AeRc